Greenwich LifeSciences (GLSI) Accounts Payables (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of Accounts Payables data on file, last reported at $4.9 million in Q4 2025.

• Quarterly Accounts Payables rose 73.91% year-over-year to $4.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.9 million (up 73.91% YoY) and the FY2025 annual result came in at $4.9 million, up 73.91% from the prior year.
• Accounts Payables advanced to $4.9 million in Q4 2025, from $1.1 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $4.9 million in Q4 2025 to a low of $220845.0 in Q4 2021.
• A 5-year average of $859861.3 and a median of $323522.5 in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2021 — Accounts Payables tumbled 68.94% — and 2024, when it jumped 1169.19%.
• Tracing GLSI's Accounts Payables over 5 years: stood at $220845.0 in 2021, then changed by 0.0% to $220845.0 in 2022, then changed by 0.0% to $220845.0 in 2023, then jumped by 1169.19% to $2.8 million in 2024, then soared by 73.91% to $4.9 million in 2025.
• The last three Accounts Payables figures came in at $4.9 million (Q4 2025), $1.1 million (Q3 2025), and $1.3 million (Q2 2025), per Business Quant data.